Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy SBRA Stock  Free SBRA Stock Alerts

Sabra Health Care REIT (SBRA) Financials

Sabra Health Care REIT logo
$17.28 -0.14 (-0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$17.40 +0.12 (+0.69%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Sabra Health Care REIT

Annual Income Statements for Sabra Health Care REIT

This table shows Sabra Health Care REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 69 60 148 269 69 138 -113 -78 14 127
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 20 17 127
Total Pre-Tax Income 		80 71 159 288 79 156 81 22 19 128
Total Revenue		 241 265 320 625 647 586 437 518 536 591
Net Interest Income / (Expense)		 0.00 0.00 -88 0.00 0.00 0.00 -99 -105 -113 -115
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 88 0.00 0.00 0.00 99 105 113 115
Long-Term Debt Interest Expense		 - - 88 - - - 99 105 113 115
Total Non-Interest Income		 241 265 408 625 647 586 535 623 649 706
Service Charges on Deposit Accounts		 3.51 7.79 26 - - 156 156 187 236 285
Other Service Charges		 28 38 18 91 212 14 18 36 38 40
Net Realized & Unrealized Capital Gains on Investments		 -0.16 -6.68 -0.55 -2.92 -16 -14 -35 -0.41 -1.54 0.00
Other Non-Interest Income		 210 225 364 537 452 431 397 401 376 381
Provision for Credit Losses		 - - - - - - 3.94 0.14 0.19 -0.57
Total Non-Interest Expense		 161 193 213 466 571 447 556 484 440 465
Other Operating Expenses		 16 18 32 37 31 33 35 40 47 50
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170
Impairment Charge		 0.00 30 1.33 1.41 122 4.00 9.50 94 14 18
Other Special Charges		 75 76 35 236 236 234 333 163 195 227
Nonoperating Income / (Expense), net		 - - 52 128 2.30 - 12 -12 -77 2.10
Income Tax Expense		 0.75 1.05 0.65 3.01 3.40 0.71 1.85 1.24 2.00 1.01
Other Adjustments to Consolidated Net Income / (Loss)		 - - - - - - - -98 -2.90 -0.40
Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54
Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 206.22M 219.07M 230.95M 231.20M 233.50M
Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54
Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 207.25M 219.07M 230.95M 232.79M 236.05M
Weighted Average Basic & Diluted Shares Outstanding		 62.30M 65.30M 105.80M 178.40M 205.27M 210.72M 230.90M 231.16M 231.48M 237.91M
Cash Dividends to Common per Share		 $1.60 $1.67 $1.73 $1.80 $1.80 $1.35 $1.20 $1.20 $1.20 $1.20

Quarterly Income Statements for Sabra Health Care REIT

This table shows Sabra Health Care REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -50 -85 -9.49 21 -15 17 26 24 30 47
Consolidated Net Income / (Loss)		 -50 -85 -9.49 21 -15 17 26 24 30 47
Net Income / (Loss) Continuing Operations		 -50 13 -9.49 22 -14 19 26 24 30 47
Total Pre-Tax Income 		-45 3.49 -7.92 22 -14 18 27 24 29 47
Total Revenue		 115 137 132 133 136 135 139 147 149 156
Net Interest Income / (Expense)		 -27 -28 -29 -28 -28 -28 -28 -29 -29 -28
Total Interest Expense		 27 28 29 28 28 28 28 29 29 28
Long-Term Debt Interest Expense		 27 28 29 28 28 28 28 29 29 28
Total Non-Interest Income		 142 165 160 161 164 163 168 176 178 184
Service Charges on Deposit Accounts		 48 53 57 58 60 61 66 68 74 77
Other Service Charges		 9.93 8.97 9.07 8.46 11 9.13 9.70 9.18 9.70 11
Other Non-Interest Income		 84 103 96 94 93 93 92 99 95 96
Provision for Credit Losses		 -0.22 0.15 -0.21 0.43 0.33 -0.36 -0.14 -0.16 -0.15 -0.13
Total Non-Interest Expense		 164 116 119 102 103 116 113 125 114 115
Other Operating Expenses		 9.68 11 11 9.53 11 17 12 13 12 13
Depreciation Expense		 47 50 53 44 43 43 43 42 43 42
Other Special Charges		 46 34 49 49 49 49 55 55 59 59
Nonoperating Income / (Expense), net		 -0.08 -7.43 -22 -7.83 -47 -0.73 0.00 1.78 -5.75 6.06
Income Tax Expense		 0.58 0.12 0.73 0.33 0.46 0.49 0.45 0.44 -0.27 0.38
Basic Earnings per Share		 ($0.22) ($0.37) ($0.04) $0.09 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20
Weighted Average Basic Shares Outstanding		 230.98M 230.95M 231.16M 231.20M 231.22M 231.20M 231.45M 231.62M 234.29M 233.50M
Diluted Earnings per Share		 ($0.22) ($0.37) ($0.04) $0.09 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20
Weighted Average Diluted Shares Outstanding		 230.98M 230.95M 231.16M 232.24M 231.22M 232.79M 233.37M 233.75M 237.04M 236.05M
Weighted Average Basic & Diluted Shares Outstanding		 230.98M 231.16M 231.20M 231.22M 231.22M 231.48M 231.50M 234.26M 236.59M 237.91M

Annual Cash Flow Statements for Sabra Health Care REIT

This table details how cash moves in and out of Sabra Health Care REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -54 17 552 -527 -11 16 50 -62 -6.60 20
Net Cash From Operating Activities		 121 176 136 361 372 355 356 316 301 311
Net Cash From Continuing Operating Activities		 121 176 136 361 372 355 356 316 301 311
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 -78 14 127
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127
Provision For Loan Losses		 13 5.54 17 39 1.24 1.86 3.94 0.14 0.19 -0.57
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170
Amortization Expense		 5.28 5.68 7.78 10 10 8.42 8.37 11 12 10
Non-Cash Adjustments to Reconcile Net Income		 -20 21 -73 -141 134 32 256 214 94 27
Changes in Operating Assets and Liabilities, net		 -20 4.97 -88 -18 -24 -2.74 23 -20 -2.73 -23
Net Cash From Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109
Net Cash From Continuing Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109
Purchase of Property, Leasehold Improvements and Equipment		 -3.69 -1.00 -6.95 -28 -25 -47 -43 -54 -85 -55
Purchase of Investment Securities		 -524 -171 -440 -672 -64 -111 -397 -267 -106 -156
Sale and/or Maturity of Investments		 33 314 183 434 347 22 104 101 289 102
Other Investing Activities, net		 - - 3.76 6.87 5.08 0.00 0.00 4.60 5.46 0.00
Net Cash From Financing Activities		 314 -301 599 -629 -646 -202 30 -162 -410 -182
Net Cash From Continuing Financing Activities		 314 -300 599 -629 -646 -202 30 -162 -410 -182
Issuance of Debt		 289 69 434 0.00 639 0.00 792 204 -92 0.00
Repayment of Debt		 -3.13 -244 -4.15 -159 -1,483 -3.07 -798 -81 -1.98 13
Repurchase of Common Equity		 - - - -0.50 - 80 - - - 86
Payment of Dividends		 -110 -119 -182 -325 -335 -278 -263 -277 -277 -280
Other Financing Activities, Net		 -1.27 -5.94 351 -0.49 -16 -0.83 -9.32 -2.52 -36 -0.09
Cash Interest Paid		 54 59 70 138 124 93 85 98 102 105
Cash Income Taxes Paid		 0.66 0.85 0.71 1.80 3.91 2.44 1.84 1.66 1.67 1.39

Quarterly Cash Flow Statements for Sabra Health Care REIT

This table details how cash moves in and out of Sabra Health Care REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -40 23 -15 -6.34 6.75 7.60 19 -24 27 -2.44
Net Cash From Operating Activities		 108 68 68 70 83 79 53 80 98 80
Net Cash From Continuing Operating Activities		 108 68 68 70 83 79 53 80 98 80
Net Income / (Loss) Continuing Operations		 -50 -85 -9.49 21 -15 17 26 24 30 47
Consolidated Net Income / (Loss)		 -50 -85 -9.49 21 -15 17 26 24 30 47
Provision For Loan Losses		 -0.22 0.15 -0.21 0.43 0.33 -0.36 -0.14 -0.16 -0.15 -0.13
Depreciation Expense		 47 50 53 44 43 43 43 42 43 42
Amortization Expense		 2.80 2.79 3.01 3.08 3.09 3.09 3.07 3.07 2.61 1.73
Non-Cash Adjustments to Reconcile Net Income		 80 116 31 7.17 45 11 8.33 14 8.79 -3.89
Changes in Operating Assets and Liabilities, net		 28 -16 -8.62 -5.68 6.65 4.91 -28 -2.05 14 -6.75
Net Cash From Investing Activities		 -57 -31 113 -8.19 60 -62 -13 -57 -57 19
Net Cash From Continuing Investing Activities		 -57 -31 113 -8.19 60 -62 -13 -57 -57 19
Purchase of Property, Leasehold Improvements and Equipment		 -14 -21 -20 -18 -26 -21 -13 -12 -14 -16
Purchase of Investment Securities		 -65 -49 -53 -12 -0.90 -41 -1.30 -56 -80 -19
Sale and/or Maturity of Investments		 23 33 184 19 86 -0.20 0.39 6.96 36 59
Other Investing Activities, net		 -1.33 5.43 1.43 2.70 0.70 0.63 0.62 4.11 0.60 -5.32
Net Cash From Financing Activities		 -92 -14 -196 -68 -136 -9.36 -20 -46 -14 -101
Net Cash From Continuing Financing Activities		 -92 -14 -196 -68 -136 -9.36 -20 -46 -14 -101
Issuance of Debt		 -142 204 -106 20 -66 61 52 -15 22 -59
Repayment of Debt		 123 -148 -0.49 -0.49 -0.50 -0.50 -0.50 -0.51 -0.51 14
Payment of Dividends		 -69 -69 -69 -69 -69 -69 -69 -69 -70 -71
Other Financing Activities, Net		 -2.50 -0.01 -18 -18 -0.01 -0.01 -0.08 - - -0.01
Cash Interest Paid		 19 29 22 30 20 29 20 30 21 34

Annual Balance Sheets for Sabra Health Care REIT

This table presents Sabra Health Care REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304
Cash and Due from Banks		 7.43 26 519 50 39 59 112 49 41 60
Restricted Cash		 9.81 9.00 69 9.43 10 6.45 3.89 4.62 5.43 5.87
Trading Account Securities		 - - 0.00 340 319 289 97 135 137 122
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 2,040 2,010 5,994 5,854 5,341 5,285 5,163 4,959 4,617 4,514
Intangible Assets		 - 26 167 131 102 83 54 40 31 27
Other Assets		 300 195 283 281 258 263 537 559 554 574
Total Liabilities & Shareholders' Equity		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304
Total Liabilities		 1,415 1,250 3,595 3,411 2,581 2,576 2,587 2,691 2,584 2,562
Short-Term Debt		 255 26 641 624 - - 0.00 197 94 107
Other Short-Term Payables		 35 40 103 95 - 146 143 142 137 118
Long-Term Debt		 1,125 1,185 2,753 2,608 2,402 2,372 2,394 2,310 2,320 2,311
Other Long-Term Liabilities		 - 0.00 98 84 179 58 50 42 33 27
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,054 1,016 3,437 3,255 3,488 3,409 3,380 3,056 2,803 2,741
Total Preferred & Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741
Preferred Stock		 0.06 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741
Common Stock		 1,203 1,210 3,639 3,510 4,074 4,165 4,485 4,489 4,497 4,595
Accumulated Other Comprehensive Income / (Loss)		 -7.33 -1.80 11 12 -12 -40 -10 19 24 21
Other Equity Adjustments		 -142 -192 -217 -272 -573 -716 -1,095 -1,452 -1,718 -1,875

Quarterly Balance Sheets for Sabra Health Care REIT

This table presents Sabra Health Care REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 5,845 5,556 5,524 5,381 5,374 5,351 5,366
Cash and Due from Banks		 26 34 27 33 60 36 63
Restricted Cash		 4.86 5.15 5.15 5.60 6.00 5.91 5.97
Trading Account Securities		 208 139 140 136 132 130 131
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 5,019 4,797 4,752 4,603 4,577 4,566 4,574
Intangible Assets		 48 39 36 33 28 28 29
Other Assets		 539 542 564 570 571 585 563
Total Liabilities & Shareholders' Equity		 5,845 5,556 5,524 5,381 5,374 5,351 5,366
Total Liabilities		 2,636 2,580 2,581 2,512 2,607 2,589 2,621
Short-Term Debt		 139 80 101 33 146 130 153
Other Short-Term Payables		 145 143 122 128 113 113 123
Long-Term Debt		 2,308 2,317 2,320 2,317 2,317 2,316 2,318
Other Long-Term Liabilities		 44 40 39 34 31 30 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,209 2,976 2,944 2,869 2,767 2,762 2,745
Total Preferred & Common Equity		 3,209 2,976 2,944 2,869 2,767 2,762 2,745
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,209 2,976 2,944 2,869 2,767 2,762 2,745
Common Stock		 4,487 4,490 4,491 4,494 4,498 4,539 4,577
Accumulated Other Comprehensive Income / (Loss)		 19 17 32 40 31 31 17
Other Equity Adjustments		 -1,297 -1,531 -1,580 -1,665 -1,762 -1,808 -1,849

Annual Metrics and Ratios for Sabra Health Care REIT

This table displays calculated financial ratios and metrics derived from Sabra Health Care REIT's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 44.69% 9.78% 20.91% 95.41% 3.60% -9.43% -25.54% 18.59% 3.43% 10.29%
EBITDA Growth		 57.51% -2.10% 57.28% 57.83% -25.59% 20.76% -80.37% 265.38% 24.97% 5.33%
EBIT Growth		 70.82% -11.12% 50.21% 48.95% -51.73% 80.88% -188.92% 127.22% 182.90% 32.26%
NOPAT Growth		 69.23% -11.56% 51.77% 48.00% -53.32% 110.58% -56.90% -52.47% 167.89% 47.00%
Net Income Growth		 69.23% -11.56% 125.60% 76.23% -75.27% 100.55% -181.82% 31.48% 117.73% 821.14%
EPS Growth		 42.31% -17.12% 52.17% 7.86% -75.50% 81.08% -177.61% 34.62% 117.65% 800.00%
Operating Cash Flow Growth		 41.91% 45.27% -22.82% 165.55% 3.30% -4.73% 0.43% -11.41% -4.80% 3.32%
Free Cash Flow Firm Growth		 61.53% 186.43% -1,720.76% 111.17% 33.25% -60.59% -71.81% 226.05% 77.91% -57.66%
Invested Capital Growth		 19.70% -8.52% 206.87% -5.05% -9.19% -1.85% -0.13% -3.65% -6.23% -1.11%
Revenue Q/Q Growth		 -5.22% -3.00% 4.06% -11.30% 41.16% 5.66% -26.99% 19.48% -0.30% 3.63%
EBITDA Q/Q Growth		 3.67% -3.20% 41.93% -36.16% 229.83% 41.24% -73.67% 38.10% 45.30% 8.01%
EBIT Q/Q Growth		 1.88% -5.74% 44.86% -55.34% 169.66% 214.64% -319.46% 230.46% 4,650.14% 24.28%
NOPAT Q/Q Growth		 0.93% -2.65% 37.37% -61.17% 324.67% 256.24% -72.43% 2,248.50% 73.49% 21.53%
Net Income Q/Q Growth		 3.72% -2.65% 104.19% -30.65% 597.57% 233.92% -336.92% -356.23% 115.57% 30.40%
EPS Q/Q Growth		 -7.50% -3.16% 47.37% -36.82% 1,133.33% -6.94% -136.36% -277.78% 115.38% 28.57%
Operating Cash Flow Q/Q Growth		 29.92% 0.07% 42.38% -1.36% 5.06% -1.69% 2.45% -8.77% 3.85% 0.40%
Free Cash Flow Firm Q/Q Growth		 12.55% 3.13% -9.77% 957.74% -22.80% 86.27% 4,915.69% -35.14% -11.26% 72.12%
Invested Capital Q/Q Growth		 1.47% 1.14% 7.13% -3.70% 0.09% -0.10% -4.26% -1.64% -0.03% -1.08%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 61.62% 54.96% 71.49% 57.74% 41.47% 55.30% 14.58% 44.91% 54.26% 51.82%
EBIT Margin		 33.25% 26.93% 33.45% 25.50% 11.88% 23.72% -28.33% 6.50% 17.79% 21.33%
Profit (Net Income) Margin		 32.94% 26.54% 49.52% 44.66% 10.66% 23.60% -25.94% -14.99% 2.57% 21.45%
Tax Burden Percent		 99.07% 98.53% 99.60% 97.06% 87.13% 88.89% -140.39% -358.14% 73.74% 98.91%
Interest Burden Percent		 100.00% 100.04% 148.63% 180.45% 102.99% 111.93% -65.21% 64.34% 19.58% 101.66%
Effective Tax Rate		 0.93% 1.47% 0.41% 1.05% 4.29% 0.46% 2.29% 5.73% 10.73% 0.78%
Return on Invested Capital (ROIC)		 3.55% 3.01% 2.35% 2.37% 1.19% 2.66% 1.16% 0.56% 1.58% 2.41%
ROIC Less NNEP Spread (ROIC-NNEP)		 3.55% 3.01% 4.60% 6.03% 1.03% 1.96% -6.40% -3.90% -1.32% 2.48%
Return on Net Nonoperating Assets (RNNOA)		 4.40% 3.77% 4.76% 5.97% 0.86% 1.36% -4.49% -2.97% -1.11% 2.16%
Return on Equity (ROE)		 7.96% 6.78% 7.11% 8.34% 2.05% 4.01% -3.34% -2.41% 0.47% 4.57%
Cash Return on Invested Capital (CROIC)		 -14.38% 11.91% -99.34% 7.55% 10.82% 4.52% 1.29% 4.28% 8.01% 3.52%
Operating Return on Assets (OROA)		 3.53% 3.01% 2.30% 2.33% 1.21% 2.31% -2.07% 0.58% 1.71% 2.36%
Return on Assets (ROA)		 3.50% 2.97% 3.41% 4.08% 1.08% 2.30% -1.90% -1.33% 0.25% 2.37%
Return on Common Equity (ROCE)		 7.95% 6.78% 7.11% 8.33% 2.05% 4.01% -3.34% -2.41% 0.47% 4.57%
Return on Equity Simple (ROE_SIMPLE)		 7.53% 6.91% 4.61% 8.59% 1.98% 4.06% -3.35% -2.54% 0.49% 4.62%
Net Operating Profit after Tax (NOPAT)		 79 70 107 158 74 155 67 32 85 125
NOPAT Margin		 32.94% 26.54% 33.31% 25.23% 11.37% 26.43% 15.30% 6.13% 15.88% 21.17%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% -2.25% -3.66% 0.16% 0.70% 7.55% 4.46% 2.90% -0.07%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 66.75% 73.07% 66.55% 74.50% 88.12% 76.28% 127.43% 93.47% 82.18% 78.76%
Earnings before Interest and Taxes (EBIT)		 80 71 107 159 77 139 -124 34 95 126
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 148 145 229 361 269 324 64 233 291 306
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.59 0.81 0.54 0.55 0.79 0.77 0.72 0.78 1.07 1.47
Price to Tangible Book Value (P/TBV)		 0.59 0.83 0.57 0.58 0.81 0.79 0.73 0.79 1.08 1.48
Price to Revenue (P/Rev)		 2.59 3.10 5.84 2.88 4.26 4.46 5.54 4.58 5.60 6.81
Price to Earnings (P/E)		 9.01 13.65 12.61 6.68 39.98 18.88 0.00 0.00 217.85 31.76
Dividend Yield		 16.72% 13.30% 12.21% 17.84% 12.64% 10.69% 11.33% 11.69% 9.26% 7.06%
Earnings Yield		 11.10% 7.33% 7.93% 14.97% 2.50% 5.30% 0.00% 0.00% 0.46% 3.15%
Enterprise Value to Invested Capital (EV/IC)		 0.82 0.90 0.69 0.77 0.87 0.85 0.81 0.87 1.03 1.24
Enterprise Value to Revenue (EV/Rev)		 8.24 7.54 14.63 7.96 7.89 8.39 10.76 9.32 10.02 10.79
Enterprise Value to EBITDA (EV/EBITDA)		 13.37 13.73 20.47 13.79 19.03 15.17 73.84 20.74 18.46 20.83
Enterprise Value to EBIT (EV/EBIT)		 24.78 28.02 43.74 31.22 66.46 35.36 0.00 143.23 56.30 50.59
Enterprise Value to NOPAT (EV/NOPAT)		 25.02 28.42 43.92 31.55 69.44 31.74 70.35 151.93 63.07 50.99
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.40 11.34 34.46 13.80 13.72 13.87 13.19 15.28 17.85 20.53
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 7.19 0.00 9.90 7.63 18.64 63.17 19.89 12.43 34.89
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 1.31 1.19 0.99 0.99 0.69 0.70 0.71 0.82 0.86 0.88
Long-Term Debt to Equity		 1.07 1.17 0.80 0.80 0.69 0.70 0.71 0.76 0.83 0.84
Financial Leverage		 1.24 1.25 1.03 0.99 0.84 0.69 0.70 0.76 0.84 0.87
Leverage Ratio		 2.27 2.29 2.09 2.05 1.89 1.75 1.76 1.82 1.90 1.93
Compound Leverage Factor		 2.27 2.29 3.10 3.69 1.95 1.96 -1.15 1.17 0.37 1.96
Debt to Total Capital		 56.70% 54.38% 49.69% 49.82% 40.78% 41.03% 41.47% 45.06% 46.28% 46.86%
Short-Term Debt to Total Capital		 10.48% 1.17% 9.38% 9.62% 0.00% 0.00% 0.00% 3.54% 1.81% 2.07%
Long-Term Debt to Total Capital		 46.22% 53.21% 40.30% 40.21% 40.78% 41.03% 41.47% 41.52% 44.47% 44.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.07% 0.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 43.30% 45.61% 50.25% 50.11% 59.22% 58.97% 58.53% 54.94% 53.72% 53.14%
Debt to EBITDA		 9.29 8.33 14.85 8.96 8.94 7.32 37.62 10.78 8.31 7.90
Net Debt to EBITDA		 9.18 8.09 12.28 8.79 8.76 7.11 35.80 10.55 8.15 7.68
Long-Term Debt to EBITDA		 7.57 8.15 12.04 7.23 8.94 7.32 37.62 9.93 7.98 7.55
Debt to NOPAT		 17.38 17.24 31.86 20.50 32.63 15.30 35.84 78.95 28.38 19.34
Net Debt to NOPAT		 17.16 16.75 26.35 20.12 31.96 14.88 34.11 77.26 27.83 18.81
Long-Term Debt to NOPAT		 14.17 16.87 25.84 16.54 32.63 15.30 35.84 72.75 27.27 18.48
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.10% 0.13% 0.06% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -321 278 -4,499 503 670 264 74 243 432 183
Operating Cash Flow to CapEx		 3,282.76% 17,540.18% 1,952.67% 1,301.90% 1,463.50% 749.36% 835.60% 579.61% 354.22% 567.59%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -50.87 0.00 0.00 0.00 0.75 2.30 3.82 1.59
Operating Cash Flow to Interest Expense		 0.00 0.00 1.54 0.00 0.00 0.00 3.61 2.99 2.66 2.69
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 1.46 0.00 0.00 0.00 3.18 2.48 1.91 2.22
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.11 0.11 0.07 0.09 0.10 0.10 0.07 0.09 0.10 0.11
Fixed Asset Turnover		 0.13 0.13 0.08 0.11 0.12 0.11 0.08 0.10 0.11 0.13
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2,434 2,226 6,832 6,487 5,891 5,782 5,774 5,563 5,217 5,159
Invested Capital Turnover		 0.11 0.11 0.07 0.09 0.10 0.10 0.08 0.09 0.10 0.11
Increase / (Decrease) in Invested Capital		 401 -207 4,605 -345 -596 -109 -7.60 -211 -347 -58
Enterprise Value (EV)		 1,986 1,995 4,680 4,976 5,112 4,920 4,700 4,824 5,364 6,375
Market Capitalization		 623 819 1,868 1,799 2,759 2,613 2,421 2,371 2,997 4,024
Book Value per Share		 $16.18 $15.56 $19.26 $18.23 $18.01 $16.48 $14.78 $13.23 $12.12 $11.59
Tangible Book Value per Share		 $16.18 $15.16 $18.32 $17.50 $17.49 $16.08 $14.54 $13.06 $11.99 $11.47
Total Capital		 2,434 2,226 6,832 6,487 5,891 5,782 5,774 5,563 5,217 5,159
Total Debt		 1,380 1,211 3,394 3,232 2,402 2,372 2,394 2,507 2,414 2,418
Total Long-Term Debt		 1,125 1,185 2,753 2,608 2,402 2,372 2,394 2,310 2,320 2,311
Net Debt		 1,363 1,176 2,807 3,172 2,353 2,307 2,279 2,453 2,367 2,351
Capital Expenditures (CapEx)		 3.69 1.00 6.95 28 25 47 43 54 85 55
Net Nonoperating Expense (NNE)		 0.00 0.00 -52 -121 4.59 17 180 109 71 -1.68
Net Nonoperating Obligations (NNO)		 1,380 1,211 3,394 3,232 2,402 2,372 2,394 2,507 2,414 2,418
Total Depreciation and Amortization (D&A)		 68 74 122 202 192 185 187 199 195 180
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54
Adjusted Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 0.00 219.07M 230.95M 231.20M 233.50M
Adjusted Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54
Adjusted Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 0.00 219.07M 230.95M 232.79M 236.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.37 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.19M 65.29M 178.26M 178.32M 205.27M 0.00 230.90M 231.16M 231.48M 237.91M
Normalized Net Operating Profit after Tax (NOPAT)		 160 176 173 392 416 392 402 274 272 369
Normalized NOPAT Margin		 66.52% 66.45% 54.04% 62.78% 64.31% 66.80% 92.00% 52.85% 50.81% 62.41%
Pre Tax Income Margin		 33.25% 26.94% 49.72% 46.01% 12.23% 26.55% 18.47% 4.18% 3.48% 21.69%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 1.21 0.00 0.00 0.00 -1.25 0.32 0.84 1.09
NOPAT to Interest Expense		 0.00 0.00 1.20 0.00 0.00 0.00 0.68 0.30 0.75 1.08
EBIT Less CapEx to Interest Expense		 0.00 0.00 1.13 0.00 0.00 0.00 -1.69 -0.20 0.09 0.62
NOPAT Less CapEx to Interest Expense		 0.00 0.00 1.13 0.00 0.00 0.00 0.24 -0.22 0.00 0.61
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 138.44% 169.88% 114.97% 116.52% 486.01% 201.06% -232.15% -357.14% 2,016.92% 221.09%
Augmented Payout Ratio		 138.44% 169.88% 114.97% 116.70% 486.01% 143.20% -232.15% -357.14% 2,016.92% 153.13%

Quarterly Metrics and Ratios for Sabra Health Care REIT

This table displays calculated financial ratios and metrics derived from Sabra Health Care REIT's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 10.45% 160.32% -4.60% 3.57% 18.47% -1.17% 5.71% 10.59% 9.46% 15.26%
EBITDA Growth		 -98.55% 696.43% -22.79% 11.05% 9,518.78% -10.11% 5.97% -12.84% 1.92% 30.02%
EBIT Growth		 -611.44% 153.13% -68.80% 39.14% 165.87% -3.19% 109.37% -24.81% 7.71% 108.72%
NOPAT Growth		 -331.89% 161.07% -78.08% 24.32% 172.29% 76.83% 182.15% -25.06% 55.27% 118.88%
Net Income Growth		 -589.72% -248.82% -123.37% 26.08% 69.84% 120.20% 376.74% 13.15% 297.26% 172.18%
EPS Growth		 -540.00% -208.33% -122.22% 28.57% 68.18% 121.62% 375.00% 11.11% 285.71% 150.00%
Operating Cash Flow Growth		 2.14% -30.99% 8.20% -8.15% -23.28% 16.50% -22.69% 13.93% 17.35% 1.56%
Free Cash Flow Firm Growth		 249.39% 2,393.27% 225.36% 471.59% 33.76% 64.95% -52.45% -61.76% -91.60% -73.03%
Invested Capital Growth		 -6.23% -3.65% -6.05% -7.49% -7.73% -6.23% -2.65% -2.89% -0.06% -1.11%
Revenue Q/Q Growth		 -10.69% 19.68% -4.02% 0.95% 2.15% -0.16% 2.67% 5.61% 1.11% 5.13%
EBITDA Q/Q Growth		 -98.82% 8,846.22% 378.02% 12.57% 2.14% -16.40% 14.13% -7.41% 19.43% 6.66%
EBIT Q/Q Growth		 -329.14% 141.77% 116.48% 135.18% 8.48% -38.61% 50.65% -15.54% 55.41% 18.97%
NOPAT Q/Q Growth		 -232.55% 133.43% -9.68% 210.63% -22.93% -18.22% 44.12% -17.50% 59.68% 15.28%
Net Income Q/Q Growth		 -397.91% -69.68% 88.83% 323.34% -171.27% 213.61% 53.03% -8.68% 24.25% 56.76%
EPS Q/Q Growth		 -414.29% -68.18% 89.19% 325.00% -177.78% 214.29% 37.50% -9.09% 30.00% 53.85%
Operating Cash Flow Q/Q Growth		 41.65% -37.69% 1.04% 2.99% 18.32% -5.38% -32.95% 51.77% 21.87% -18.11%
Free Cash Flow Firm Q/Q Growth		 375.65% -35.65% 60.69% 30.36% -0.78% -20.64% -53.68% 4.85% -78.21% 154.79%
Invested Capital Q/Q Growth		 -2.45% -1.64% -3.42% -0.17% -2.71% -0.03% 0.27% -0.42% 0.12% -1.08%
Profitability Metrics		 - - - - - - - - - -
EBITDA Margin		 0.72% 53.51% 52.13% 58.13% 58.12% 48.67% 52.26% 45.82% 54.12% 54.90%
EBIT Margin		 -43.13% 15.05% 9.69% 22.58% 23.98% 14.75% 19.20% 15.35% 23.60% 26.70%
Profit (Net Income) Margin		 -43.71% -61.96% -7.21% 15.95% -11.13% 12.66% 18.87% 16.32% 20.05% 29.90%
Tax Burden Percent		 111.00% -2,431.95% 119.77% 95.58% 107.86% 93.19% 96.16% 98.53% 101.63% 98.99%
Interest Burden Percent		 91.29% 16.93% -62.10% 73.89% -43.02% 92.14% 102.23% 107.87% 83.61% 113.11%
Effective Tax Rate		 0.00% 3.55% 0.00% 1.47% 0.00% 2.68% 1.66% 1.80% -0.90% 0.81%
Return on Invested Capital (ROIC)		 -2.04% 0.70% 0.67% 2.06% 1.66% 1.37% 1.98% 1.59% 2.60% 2.97%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2.76% -3.19% -0.13% 1.72% 0.08% 1.31% 1.95% 1.66% 2.37% 3.22%
Return on Net Nonoperating Assets (RNNOA)		 -2.17% -2.43% -0.10% 1.34% 0.06% 1.10% 1.65% 1.42% 2.04% 2.80%
Return on Equity (ROE)		 -4.22% -1.73% 0.57% 3.40% 1.72% 2.46% 3.63% 3.01% 4.64% 5.78%
Cash Return on Invested Capital (CROIC)		 6.40% 4.28% 6.29% 7.90% 8.95% 8.01% 4.67% 4.79% 2.04% 3.52%
Operating Return on Assets (OROA)		 -3.10% 1.33% 0.87% 2.03% 2.30% 1.42% 1.91% 1.57% 2.50% 2.95%
Return on Assets (ROA)		 -3.14% -5.48% -0.64% 1.43% -1.07% 1.22% 1.88% 1.67% 2.13% 3.30%
Return on Common Equity (ROCE)		 -4.22% -1.73% 0.57% 3.40% 1.72% 2.46% 3.63% 3.01% 4.64% 5.78%
Return on Equity Simple (ROE_SIMPLE)		 -0.53% 0.00% -4.29% -4.19% -3.08% 0.00% 1.79% 1.89% 3.54% 0.00%
Net Operating Profit after Tax (NOPAT)		 -32 11 9.52 30 23 19 27 22 35 41
NOPAT Margin		 -27.51% 7.68% 7.23% 22.25% 16.79% 13.75% 19.30% 15.08% 23.81% 26.11%
Net Nonoperating Expense Percent (NNEP)		 0.72% 3.90% 0.80% 0.34% 1.58% 0.06% 0.02% -0.08% 0.23% -0.25%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 143.32% 84.83% 90.46% 77.09% 75.78% 85.52% 80.90% 84.76% 76.50% 73.38%
Earnings before Interest and Taxes (EBIT)		 -49 21 13 30 33 20 27 23 35 42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.82 73 69 77 79 66 73 67 80 86
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.79 0.78 0.78 0.83 1.03 1.07 1.19 1.27 1.59 1.47
Price to Tangible Book Value (P/TBV)		 0.80 0.79 0.79 0.84 1.05 1.08 1.20 1.28 1.61 1.48
Price to Revenue (P/Rev)		 5.83 4.58 4.55 4.74 5.52 5.60 6.04 6.28 7.65 6.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 217.85 66.31 66.92 44.86 31.76
Dividend Yield		 10.96% 11.69% 11.92% 11.35% 9.35% 9.26% 8.45% 7.94% 6.45% 7.06%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 1.51% 1.49% 2.23% 3.15%
Enterprise Value to Invested Capital (EV/IC)		 0.87 0.87 0.87 0.90 1.01 1.03 1.09 1.13 1.30 1.24
Enterprise Value to Revenue (EV/Rev)		 11.41 9.32 9.16 9.37 9.83 10.02 10.46 10.59 11.86 10.79
Enterprise Value to EBITDA (EV/EBITDA)		 29.36 20.74 40.99 39.63 26.39 18.46 19.46 20.94 23.85 20.83
Enterprise Value to EBIT (EV/EBIT)		 0.00 143.23 0.00 0.00 0.00 56.30 53.42 59.70 66.68 50.59
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 151.93 1,866.33 727.07 107.67 63.07 53.84 60.11 65.71 50.99
Enterprise Value to Operating Cash Flow (EV/OCF)		 14.29 15.28 14.60 15.36 18.24 17.85 19.92 20.02 21.86 20.53
Enterprise Value to Free Cash Flow (EV/FCFF)		 13.22 19.89 13.43 10.96 10.85 12.43 22.92 23.30 63.68 34.89
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.76 0.82 0.81 0.82 0.82 0.86 0.89 0.89 0.90 0.88
Long-Term Debt to Equity		 0.72 0.76 0.78 0.79 0.81 0.83 0.84 0.84 0.84 0.84
Financial Leverage		 0.79 0.76 0.75 0.78 0.79 0.84 0.85 0.85 0.86 0.87
Leverage Ratio		 1.84 1.82 1.81 1.83 1.85 1.90 1.90 1.91 1.91 1.93
Compound Leverage Factor		 1.68 0.31 -1.12 1.36 -0.79 1.75 1.95 2.06 1.60 2.18
Debt to Total Capital		 43.27% 45.06% 44.61% 45.12% 45.02% 46.28% 47.10% 46.97% 47.37% 46.86%
Short-Term Debt to Total Capital		 2.45% 3.54% 1.48% 1.87% 0.63% 1.81% 2.79% 2.50% 2.93% 2.07%
Long-Term Debt to Total Capital		 40.82% 41.52% 43.13% 43.24% 44.40% 44.47% 44.30% 44.47% 44.44% 44.80%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 56.73% 54.94% 55.39% 54.88% 54.98% 53.72% 52.90% 53.03% 52.63% 53.14%
Debt to EBITDA		 14.53 10.78 20.97 19.84 11.75 8.31 8.44 8.68 8.72 7.90
Net Debt to EBITDA		 14.35 10.55 20.63 19.58 11.55 8.15 8.22 8.53 8.47 7.68
Long-Term Debt to EBITDA		 13.71 9.93 20.28 19.02 11.58 7.98 7.94 8.22 8.18 7.55
Debt to NOPAT		 -1,655.85 78.95 954.75 364.07 47.92 28.38 23.35 24.91 24.01 19.34
Net Debt to NOPAT		 -1,634.77 77.26 939.34 359.20 47.13 27.83 22.73 24.48 23.34 18.81
Long-Term Debt to NOPAT		 -1,562.09 72.75 923.06 348.95 47.26 27.27 21.97 23.58 22.53 18.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 344 221 356 464 460 365 169 177 39 98
Operating Cash Flow to CapEx		 757.74% 327.08% 349.48% 381.08% 322.56% 373.85% 408.16% 644.89% 706.12% 515.16%
Free Cash Flow to Firm to Interest Expense		 12.71 7.94 12.46 16.37 16.34 13.07 5.95 6.05 1.31 3.51
Operating Cash Flow to Interest Expense		 4.01 2.42 2.39 2.48 2.96 2.82 1.86 2.73 3.31 2.85
Operating Cash Flow Less CapEx to Interest Expense		 3.48 1.68 1.71 1.83 2.04 2.06 1.40 2.31 2.84 2.29
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.07 0.09 0.09 0.09 0.10 0.10 0.10 0.10 0.11 0.11
Fixed Asset Turnover		 0.08 0.10 0.10 0.11 0.11 0.11 0.12 0.12 0.12 0.13
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 5,656 5,563 5,373 5,364 5,218 5,217 5,231 5,209 5,215 5,159
Invested Capital Turnover		 0.07 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.11
Increase / (Decrease) in Invested Capital		 -376 -211 -346 -434 -437 -347 -142 -155 -3.28 -58
Enterprise Value (EV)		 4,944 4,824 4,685 4,833 5,279 5,364 5,680 5,903 6,761 6,375
Market Capitalization		 2,529 2,371 2,327 2,445 2,968 2,997 3,282 3,499 4,360 4,024
Book Value per Share		 $13.89 $13.23 $12.87 $12.73 $12.41 $12.12 $11.96 $11.93 $11.72 $11.59
Tangible Book Value per Share		 $13.68 $13.06 $12.70 $12.58 $12.27 $11.99 $11.83 $11.81 $11.59 $11.47
Total Capital		 5,656 5,563 5,373 5,364 5,218 5,217 5,231 5,209 5,215 5,159
Total Debt		 2,447 2,507 2,397 2,420 2,349 2,414 2,463 2,447 2,470 2,418
Total Long-Term Debt		 2,308 2,310 2,317 2,320 2,317 2,320 2,317 2,316 2,318 2,311
Net Debt		 2,416 2,453 2,358 2,388 2,311 2,367 2,397 2,404 2,401 2,351
Capital Expenditures (CapEx)		 14 21 20 18 26 21 13 12 14 16
Net Nonoperating Expense (NNE)		 19 95 19 8.37 38 1.47 0.60 -1.82 5.58 -5.92
Net Nonoperating Obligations (NNO)		 2,447 2,507 2,397 2,420 2,349 2,414 2,463 2,447 2,470 2,418
Total Depreciation and Amortization (D&A)		 50 53 56 47 46 46 46 45 45 44
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.22) ($0.37) ($0.04) $0.09 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20
Adjusted Weighted Average Basic Shares Outstanding		 230.98M 230.95M 231.16M 231.20M 231.22M 231.20M 231.45M 231.62M 234.29M 233.50M
Adjusted Diluted Earnings per Share		 ($0.22) ($0.37) ($0.04) $0.09 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20
Adjusted Weighted Average Diluted Shares Outstanding		 230.98M 230.95M 231.16M 232.24M 231.22M 232.79M 233.37M 233.75M 237.04M 236.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 230.98M 231.16M 231.20M 231.22M 231.22M 231.48M 231.50M 234.26M 236.59M 237.91M
Normalized Net Operating Profit after Tax (NOPAT)		 43 64 49 78 57 73 84 91 65 100
Normalized NOPAT Margin		 37.92% 46.75% 36.87% 58.40% 41.97% 54.20% 60.11% 61.93% 44.09% 63.74%
Pre Tax Income Margin		 -39.37% 2.55% -6.02% 16.69% -10.32% 13.59% 19.63% 16.56% 19.73% 30.21%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -1.83 0.74 0.45 1.06 1.16 0.72 0.94 0.77 1.19 1.49
NOPAT to Interest Expense		 -1.16 0.38 0.33 1.04 0.81 0.67 0.95 0.76 1.20 1.45
EBIT Less CapEx to Interest Expense		 -2.35 0.00 -0.24 0.41 0.24 -0.04 0.48 0.35 0.72 0.93
NOPAT Less CapEx to Interest Expense		 -1.69 -0.36 -0.35 0.39 -0.11 -0.09 0.49 0.33 0.73 0.90
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 -1,625.33% -357.14% -217.11% -224.88% -313.96% 2,016.92% 560.72% 531.00% 286.65% 221.09%
Augmented Payout Ratio		 -1,625.33% -357.14% -217.11% -224.88% -313.96% 2,016.92% 560.72% 531.00% 286.65% 153.13%

Frequently Asked Questions About Sabra Health Care REIT's Financials

When does Sabra Health Care REIT's financial year end?

According to the most recent income statement we have on file, Sabra Health Care REIT's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Sabra Health Care REIT's net income changed over the last 9 years?

Sabra Health Care REIT's net income appears to be on a downward trend, with a most recent value of $126.71 million in 2024, rising from $79.38 million in 2015. The previous period was $13.76 million in 2023. See where experts think Sabra Health Care REIT is headed by visiting Sabra Health Care REIT's forecast page.

How has Sabra Health Care REIT revenue changed over the last 9 years?

Over the last 9 years, Sabra Health Care REIT's total revenue changed from $240.96 million in 2015 to $590.70 million in 2024, a change of 145.1%.

How much debt does Sabra Health Care REIT have?

Sabra Health Care REIT's total liabilities were at $2.56 billion at the end of 2024, a 0.8% decrease from 2023, and a 81.1% increase since 2015.

How much cash does Sabra Health Care REIT have?

In the past 9 years, Sabra Health Care REIT's cash and equivalents has ranged from $7.43 million in 2015 to $518.63 million in 2017, and is currently $60.47 million as of their latest financial filing in 2024.

How has Sabra Health Care REIT's book value per share changed over the last 9 years?

Over the last 9 years, Sabra Health Care REIT's book value per share changed from 16.18 in 2015 to 11.59 in 2024, a change of -28.4%.


Related Companies

This page (NASDAQ:SBRA) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...
Stansberry Research | Sponsored
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored